Clinical Study
Evidence of Stage- and Age-Related Heterogeneity of Non-HLA SNPs and Risk of Islet Autoimmunity and Type 1 Diabetes: The Diabetes Autoimmunity Study in the Young
Table 2
Association between non-HLA T1D candidate SNPs and development of IA, progression from IA to T1D, and development of T1D adjusted for HLA-DR3/4, DQB1*0302 genotype and first degree relative with T1D.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CI: confidence interval; DAISY: Diabetes Autoimmunity Study in the Young; HLA: human leukocyte antigen; HR: hazard ratio; IA: islet autoimmunity; MAF: minor allele frequency; T1D: type 1 diabetes. aMinor allele frequency (MAF) calculated for children negative for IA. bAdjusted for HLA-DR3/4, DQB1*0302 genotype and first degree relative with T1D. TLR8 (rs5979785) is additionally adjusted for sex because it is on the X chromosome. cAdjusted for HLA-DR3/4, DQB1*0302 genotype, first degree relative with T1D, and age at first antibody positive visit. TLR8 (rs5979785) is additionally adjusted for sex because it is on the X chromosome. dSNP analyzed additively with HR representing increase in risk for each additional minor allele. eSNP analyzed dichotomously with HR representing increase in risk for at least one minor allele. *SNP rs10517086 did not meet the assumptions of proportional hazards in the development of IA analysis and therefore was modeled using a restricted cubic spline (Figure 1). |